Crescent Biopharma
CBIO
50 hedge funds and large institutions have $135M invested in Crescent Biopharma in 2016 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 3 closing their positions.
667% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more funds holding
Funds holding: 30 → 50 (+20)
61% more capital invested
Capital invested by funds: $83.5M → $135M (+$51.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$16.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$2.63M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.62M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.69M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$344K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$82K |
| 3 |
SIM
Spark Investment Management
New York
|
-$75.1K |
| 4 |
Morgan Stanley
New York
|
-$12.4K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$11.7K |
CBIO Hedge Fund Activity: Q2 2016 in Review
50 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2016, worth a combined $135M — up 61% from $83.5M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CBIO positions and 3 closed out — a net gain of 20 holders — while 15 added to existing stakes and 5 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $16.9M. The largest seller was Candriam SCA, cutting an estimated $344K.
- 50 institutional investors held Crescent Biopharma (CBIO) as of Q2 2016, up from 30 in Q1 2016.
- Funds reported $135M of Crescent Biopharma stock for Q2 2016, up 61% quarter-over-quarter.
- 23 funds opened new Crescent Biopharma positions in Q2 2016 and 3 closed out, a net change of +20 holders.
- The largest Crescent Biopharma buyer in Q2 2016 was BVF Inc, an estimated $16.9M added.
- The largest Crescent Biopharma seller in Q2 2016 was Candriam SCA, an estimated $344K sold.
Based on aggregated 13F filings for Q2 2016.